Leerink Partners Assumes AbCellera Biologics at Outperform, Announces Price Target of $5

Benzinga · 07/07 12:39
Leerink Partners analyst Faisal Khurshid assumes AbCellera Biologics (NASDAQ:ABCL) with a Outperform rating and announces Price Target of $5.